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Acquired thrombotic thrombocytopenic purpura in a
child: rituximab to prevent relapse. A pediatric report
and literature review. 
Thrombotic thrombocytopenic purpura (TTP) is a life-
threatening thrombotic microangiopathy (TMA), charac-
terized by peripheral thrombocytopenia, microangio-
pathic hemolytic anemia (MAHA) and severe deficiency
of a disintegrin and metalloproteinase with trom-
bospondin type 1 motif, member 13 (ADAMTS13),
required for the cleavage of von Willebrand factor (vWF).
The absence of ADAMTS13 leads to an inappropriate
cleavage of ultra large multimers of vWF (ULvWF) that
causes platelet aggregates and microvascular thrombosis
mostly in the brain, kidney and heart. TTP may be con-
genital or familial due to a mutation in the ADAMTS13
gene leading to an enzyme deficiency, or it may be
acquired due to an inhibitor of ADAMTS13 activity.
Diagnosis of TTP was originally formulated on the basis
of a clinical pentad, including thrombocytopenia,
MAHA, neurological signs, renal dysfunction, and fever.
However, 35% of patients do not present neurological or
renal abnormalities, thus, according to the current guide-
lines, the presence of thrombocytopenia and non-
autoimmune MAHA anemia are sufficient for a diagnosis
of TTP. Acquired TTP is a rare disorder with an inci-
dence, in UK adult patients, of six cases per million per
year.1 In infants, TTP is a very uncommon disease, and
congenital TTP is more prevalent than the acquired form.
In children, the differential diagnosis with hemolytic ure-
mic syndrome (HUS) is mandatory. HUS is more frequent
and has a clinical presentation similar to that of TTP, but
it is profoundly distinct with regard to both pathophysi-
ology and management. ADAMTS13 activity is typically
normal in children with HUS, while a severe ADAMTS13
deficiency defines children with TTP. Thus, the evalua-
tion of ADAMTS13 activity and the search for inhibitor
antibodies are crucial for a differential diagnosis.2  The
standard treatment of acquired TTP consists mainly of
daily therapeutic plasma exchange (PEX). PEX removes
the inhibitors and the ULvWF multimers that cause
platelet aggregates, and also replenishes ADAMTS13. It
is necessary for PEX to be performed on a daily basis until
the platelet count has stably recovered. The emerging
consideration of TTP as an autoimmune disorder has led
to a large use of immunosuppressive treatment with
steroids during PEX. This approach has impacted on the
historically fatal prognosis of TTP in the current 90% sur-
vival rates. Approximately 10-20% of TTP patients are
refractory to PEX and require an additional immunosup-
pressive treatment. Rituximab, a humanized monoclonal
antibody directed against the B-cell antigen CD20,
inhibits autoantibody formation and is now routinely
recommended in the acute phase of TTP for adult
patients with a suboptimal response to primary therapy.1
Up to 40% of adult patients who are responsive to first-
line treatment will relapse. Rituximab is effective in
relapsed TTP resulting in a response rate greater than
90%.1 The prevention of relapse represents a major goal.
Rituximab, used as a preemptive therapy, reduces the
incidence of relapse in adult patients in clinical remission
with persistent severe ADAMT13 deficiency, or when
ADAMTS13 becomes <10% during follow up.3 
We herein report the case of an 11-year-old girl with
acquired TTP who was treated with rituximab to prevent
clinical relapse. The child was admitted to our
Hematology Center with a fever (38°C) and petechiae.
The physical and neurological examination was normal.
Blood testing showed anemia (Hemoglobin [Hb] 8.8
g/dL) with an increase of hemolysis indices: reticulocyto-
sis was 119x109/L (normal range: 22-139), lactate dehy-
drogenase (LDH) 4715 UI/L (normal range: 120-300),
total bilirubin 2.62 mg/dL (normal range: 0.35-1), and a
low haptoglobin level without schistocytes; she also
showed a normal white blood cell count (7x109/L) and
severe thrombocytopenia (platelet count 9x109/L), with-
out renal involvement. Blood coagulation tests were nor-
mal. The direct antiglobulin test was negative. Hepatitis
screening for the hepatitis B virus (HBV), hepatitis C virus
(HCV), and human immunodeficiency virus (HIV) proved
negative. Her family medical history was silent for relat-
ed diseases. A bone marrow aspirate showed adequate
granulopoiesis, erythropoiesis and megakaryocytes with
normal morphology. An autoimmune work-up - antinu-
clear antibodies (ANA), double stranded DNA (dsDNA),
extractable nuclear antigens (ENA), Complement 3 (C3)
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Table 1. Summary of published reports on the use of rituximab in pediatric thrombotic thrombocytopenic purpura.
Reference N° patients Rituximab Usage Follow up Relapses
(months)
Curtillet et al. 20067 1 Refractory 3 −
Binder et al. 20108 1 Refractory 12 −
McDonald et al. 20109 6 Refractory 38, 35, 24, 16, 12, 9 −, 1, 1, −, −, −
Harambat et al. 201110 1 Refractory 18 −
Narayanan et al. 201211 1 Refractory 12 −
Albaramki et al. 200912 2 Refractory, Relapse 12,17 −
Wieland et al. 201514 7 Refractory, Relapse 144, 72, 48, 36, 24, 12, lost to follow up −, 2,−, −, 3, 3, 1
Sankararaman et al. 201413 1 Relapse 29 −
Joly et al. 20165 7 Refractory/Relapse 6-16 (years) NA
7 Preemptive 6-16 (years) NA
Jayabose et al. 201115 1 Preemptive 46 −
Present report 2017 1 Preemptive 6 −
NA: not available.
and Complement 4 (C4) - was carried out and resulted
negative. The child was treated with intravenous human
immunoglobulins (0.4 g/kg/day) for three days and pred-
nisone (1 mg/kg/die) on the suspicion of an autoimmune
bicytopenia. Because of a clinical deterioration and no
response to intravenous human immunoglobulin thera-
py, a peripheral blood smear was reevaluated and
showed schistocytes (60/1000 cells per microscope field).
ADAMTS13 activity was immediately tested and PEX
promptly started (replacement with fresh frozen plasma
30 ml/kg), in association with continuous plasma infu-
sion (10 ml/kg) and dexamethasone (12 mg/day). The
ADAMTS13 activity was less than 3% and the presence
of inhibitor antibodies confirmed the diagnosis of
acquired TTP.1 The patient underwent five daily PEX
with a rise in the platelet count (>150x109/L); PEX was
then performed every other day for one week, and the
final PEX one week later. The child was discharged, and
oral steroid therapy was tapered and stopped over the
course of four months. One month after the last PEX,
ADAMTS13 activity was normal (100%). ADAMTS13
activity was monitored every six months; 27 months
later, ADAMTS13 activity fell to 3% with the reappear-
ance of inhibitor antibodies. Taking into account that the
occurrence of severe ADAMTS13 deficiency during
remission may predict the risk of relapse,4 we decided to
treat the patient with preemptive rituximab at a dose of
375 mg/m2/week for four weeks, preceded by the infu-
sion of antihistamines, steroids (dexamethasone 4 mg)
and antipyretics. ADAMTS13 activity after the first, sec-
ond and fourth infusion was 9%, 70% and 95%, respec-
tively. The treatment was well tolerated without infec-
tive complications. Currently, after one year of follow up,
the girl is in clinical remission with normal ADAMTS13
activity without inhibitor antibodies; ADAMTS13 activi-
ty is monitored every six months (Figure 1).
Herein, we report the case of a pediatric patient with
acquired TTP who was successfully treated with ritux-
imab to prevent hematological relapse. Acquired TTP in
childhood (age <18 years) is a very rare disease, often
misdiagnosed; the epidemiology of childhood TTP, as
well as the best first-line treatment and the role of pre-
emptive strategies are not known. Retrospective studies
from registries have shown that the rate of annual inci-
dence is approximately 3%  in adults, and that it is more
frequent in females and adolescents (age >10 years).2,5
The idiopathic form is more common. Acquired TTP in
children appears to be the same disorder that occurs in
adults, requiring a similar management and long-term
follow up, as well as an awareness of the possibility of
relapse.6 Indeed,  a high relapse rate is observed after
first-line treatment, and relapses are more frequent in
acquired TTP.2 Few reports in the literature indicate that
rituximab has gained favor as an adjunctive agent to treat
refractory or relapsing TTP in children.5,7-11 During
relapse, children undergo PEX and thereafter receive
standard dose rituximab.5,12-14 Encouraging results have
been observed, with complete remission rates ranging
between 82% and 100%, and the depletion of B cells
induced by rituximab leads to long-term remissions
(median 7.7 years, range: 2-12.7).14 Treatment is well tol-
erated, with no severe side effects. In our experience,
severe ADAMTS13 deficiency with the presence of
inhibitor antibodies confirmed the diagnosis of acquired
TTP in an adolescent girl. A prompt and complete
response was achieved following treatment with PEX
and steroids, with a normalization of ADAMTS13 activ-
ity. Careful monitoring allowed us to identify an
increased risk of TTP recurrence due to a reduction in
activity (<3% in two consecutive controls) and the reap-
pearance of the inhibitor antibody. In fact, during the
remission phase, the persistence of an undetectable
ADAMTS13 activity (<5%) and the presence of inhibitor
antibodies is considered a predisposing factor to clinical
relapse.1 In this setting, the use of preemptive rituximab
has demonstrated to be an effective treatment to prevent
hematological recurrence in adult patients.3 In children,
rituximab as preemptive therapy has been used in eight
cases alone.5,15 In our patient, taking into account the
increased risk of mortality or psychomotor and psy-
chosocial sequelae due to TTP relapse, we utilized pre-
emptive rituximab 27 month after diagnosis. The treat-
ment was well tolerated and was followed by a rapid
normalization of ADAMTS13 activity and inhibitor dis-
appearance. ADAMTS13 monitoring was continued
every six months showing persistent normal
ADAMTS13 levels after one year of follow up. The long-
term effects of rituximab in children are unknown. A
recent study based on The International Classification of
Diseases has shown a significantly increased risk of infec-
tious complications associated with rituximab treatment
in children with immunological and onco-hematological
diseases, but these were related to the underlying condi-
tion. The case herein has clearly shown that the regular
monitoring of both ADAMTS13 activity and inhibitor
levels is of the utmost importance in order to identify
children at risk for relapse. Rituximab is an effective pre-
emptive therapy which assists in the avoidance of conse-
quences and sequelae on the growth and  social life of the
child. Acquired TTP is a rare disorder in childhood,
hence, it is important to collect all observed data in order
to have more information about which is the best treat-
ment and outcome. 
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Figure 1. Level of ADAMTS 13 activity due to treatment. PEX: plasma
exchange; RTX: rituximab.
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